Establishment and Characterization of a Novel Human Clear-cell Sarcoma of Soft-tissue Cell Line, RSAR001, Derived from Pleural Effusion of a Patient with Pleural Dissemination

Hakozaki, Michiyuki; Tamura, Haruka; Dobashi, Yuu; Yoshida, Aki; Kato, Kouki; Tajino, Takahiro; Yamada, Hitoshi; Kaneuchi, Yoichi; Katahira, Kentaro; Ezaki, Junji; Waguri, Satoshi; Konno, Satoshi; Watanabe, Shinya

doi:10.21873/anticanres.12822

Cited by 3 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In most cases, CCS cells have a strong immuno-histological staining of HMB-45, melan-A, and S100 [96]. The detection of translocation has been confirmed by PCR and sequencing in several studies [97][98][99][100]; however, no major study of monitoring disease activity via liquid biopsy has been reported. As the survival rates for CCS are~40% at 10 years compared to~60% at five years [101], long-term liquid biopsy surveillance may improve patient outcomes for this slow-growing tumour.…”

Section: Clear Cell Sarcoma Of Soft Tissuementioning

confidence: 98%

Rationale for Early Detection of EWSR1 Translocation-Associated Sarcoma Biomarkers in Liquid Biopsy

Clanchy

2021

Cancers

View full text Add to dashboard Cite

Sarcomas are mesenchymal tumours that often arise and develop as a result of chromosomal translocations, and for several forms of sarcoma the EWSR1 gene is a frequent translocation partner. Sarcomas are a rare form of malignancy, which arguably have a proportionally greater societal burden that their prevalence would suggest, as they are more common in young people, with survivors prone to lifelong disability. For most forms of sarcoma, histological diagnosis is confirmed by molecular techniques such as FISH or RT-PCR. Surveillance after surgical excision, or ablation by radiation or chemotherapy, has remained relatively unchanged for decades, but recent developments in molecular biology have accelerated the progress towards routine analysis of liquid biopsies of peripheral blood. The potential to detect evidence of residual disease or metastasis in the blood has been demonstrated by several groups but remains unrealized as a routine diagnostic for relapse during remission, for disease monitoring during treatment, and for the detection of occult, residual disease at the end of therapy. An update is provided on research relevant to the improvement of the early detection of relapse in sarcomas with EWSR1-associated translocations, in the contexts of biology, diagnosis, and liquid biopsy.

show abstract